Q1 2022 Results

Company overview Financial review 2022 priorities Appendix References References ENTRESTO 1 IQVIA National Prescription Audit as of 25/03/2022. 2 Approved indications differ by geography. Examples include "indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with CHF. Benefits are most clearly evident in patients with LVEF below normal." (US) HFrEF (EU) HFrEF and HTN (China and JP). 3 Zhang et al., ESC Heart Failure 2020; 7: 3841 4 Proudfoot et al., Int J Cardiol. 2021; 331:164 5 Including, but not limited to, the recent 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (Heidenreich et al., J Am Coll Cardiol. 2022) KESIMPTA 1 Hauser S, et. al. Long-term safety of ofatumumab in patients with relapsing multiple sclerosis. Presented at American Academy of Neurology 2022 (S14.004). 2 Hauser S. et al. Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis. Presented at American Academy of Neurology 2022 (P5.004) 3 Ziemssen T, et al. KYRIOS clinical trial: Tracking the immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. Presented at American Academy of Neurology 2022, Levit E, et al. Mult Scler Relat Disord. 2022 Mar 3;60:103719 4 Based on SHP APLD representing 9K patients through Jan 2022 * *IQVIA National Prescription Audit (NPA) data projected and scaled to IQVIA National Sales Perspectives (NSP) volume (national derivative of IQVIA Drug Distribution Data (DDD)) 121 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation